# A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

> **NCT02504099** · PHASE3 · TERMINATED · sponsor: **AbbVie** · enrollment: 3 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir and dasabuvir
- **DRUG:** ombitasvir/paritaprevir/ritonavir
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT02504099
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2016-09
- **Final completion:** 2016-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study stopped due to low enrollment
- **Last updated:** 2017-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504099, "A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02504099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*